BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis
- 377 Downloads
Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of BRAF mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that BRAF V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44–0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82–2.34). In subgroup analyses, BRAF V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that BRAF mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors.
KeywordsBRAF mutation BRAF V600E Glioma Glioblastoma Overall survival Progression-free survival Meta-analysis Review
We specially thank Dr. Aden Ka-Yin Chan (Chinese University of Hong Kong) and Dr. Chul-Kee Park (Seoul National University) for providing necessary data.
Compliance with Ethical Standards
Our study protocol strictly followed the recommendation of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement .
Conflict of Interest
The authors declare that they have no conflict of interest.
No funding support to report.
- 2.Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi: 10.1007/s00401-011-0802-6 CrossRefPubMedGoogle Scholar
- 6.Bannykh S, Kandala G (2014) V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. Brain Pathol 24:76–76Google Scholar
- 7.Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6(3):e17948. doi: 10.1371/journal.pone.0017948 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysesGoogle Scholar
- 14.Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, de Seixas Alves MT, Capellano AM, Saba-Silva N, Cavalheiro S et al (2014) Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neuro-Oncol 117(2):235–242. doi: 10.1007/s11060-014-1398-1 CrossRefGoogle Scholar
- 15.Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, Esbenshade AJ, Tehrani M et al (2015) A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol 130(4):575–585. doi: 10.1007/s00401-015-1467-3 CrossRefPubMedGoogle Scholar
- 17.Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669–678. doi: 10.1007/s00401-015-1405-4 CrossRefPubMedGoogle Scholar
- 18.Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N et al (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33(9):1015–1022. doi: 10.1200/jco.2014.58.3922 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Tabouret E, Bequet C, Denicolai E, Barrie M, Nanni I, Metellus P, Dufour H, Chinot O et al (2015) BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Eur J Surg Oncol 41(12):1685–1690. doi: 10.1016/j.ejso.2015.09.012 CrossRefPubMedGoogle Scholar
- 22.Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4(1):79. doi: 10.1186/s40478-016-0351-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110. doi: 10.1016/j.ccr.2009.12.020 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173. doi: 10.1016/j.ccr.2006.02.019 CrossRefPubMedGoogle Scholar
- 28.Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM et al (2016) Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-oncologyGoogle Scholar